195 related articles for article (PubMed ID: 21465190)
1. Molecular profiles and clinical outcome of stage UICC II colon cancer patients.
Gröne J; Lenze D; Jurinovic V; Hummel M; Seidel H; Leder G; Beckmann G; Sommer A; Grützmann R; Pilarsky C; Mansmann U; Buhr HJ; Stein H; Hummel M
Int J Colorectal Dis; 2011 Jul; 26(7):847-58. PubMed ID: 21465190
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-driven gene expression is an independent prognostic factor in stage II and III colon cancer patients.
Dekervel J; Hompes D; van Malenstein H; Popovic D; Sagaert X; De Moor B; Van Cutsem E; D'Hoore A; Verslype C; van Pelt J
Clin Cancer Res; 2014 Apr; 20(8):2159-68. PubMed ID: 24486594
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles in stages II and III colon cancers: application of a 128-gene signature.
Thorsteinsson M; Kirkeby LT; Hansen R; Lund LR; Sørensen LT; Gerds TA; Jess P; Olsen J
Int J Colorectal Dis; 2012 Dec; 27(12):1579-86. PubMed ID: 22710688
[TBL] [Abstract][Full Text] [Related]
5. A potential prognostic prediction model of colon adenocarcinoma with recurrence based on prognostic lncRNA signatures.
Jin L; Li C; Liu T; Wang L
Hum Genomics; 2020 Jun; 14(1):24. PubMed ID: 32522293
[TBL] [Abstract][Full Text] [Related]
6. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.
Missiaglia E; Jacobs B; D'Ario G; Di Narzo AF; Soneson C; Budinska E; Popovici V; Vecchione L; Gerster S; Yan P; Roth AD; Klingbiel D; Bosman FT; Delorenzi M; Tejpar S
Ann Oncol; 2014 Oct; 25(10):1995-2001. PubMed ID: 25057166
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D
J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756
[TBL] [Abstract][Full Text] [Related]
8. A robust gene signature for the prediction of early relapse in stage I-III colon cancer.
Dai W; Li Y; Mo S; Feng Y; Zhang L; Xu Y; Li Q; Cai G
Mol Oncol; 2018 Apr; 12(4):463-475. PubMed ID: 29377588
[TBL] [Abstract][Full Text] [Related]
9. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer.
Maak M; Simon I; Nitsche U; Roepman P; Snel M; Glas AM; Schuster T; Keller G; Zeestraten E; Goossens I; Janssen KP; Friess H; Rosenberg R
Ann Surg; 2013 Jun; 257(6):1053-8. PubMed ID: 23295318
[TBL] [Abstract][Full Text] [Related]
10. Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy.
Turksma AW; Coupé VM; Shamier MC; Lam KL; de Weger VA; Belien JA; van den Eertwegh AJ; Meijer GA; Meijer CJ; Hooijberg E
Clin Cancer Res; 2016 Jan; 22(2):346-56. PubMed ID: 26420855
[TBL] [Abstract][Full Text] [Related]
11. Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors.
Kopetz S; Tabernero J; Rosenberg R; Jiang ZQ; Moreno V; Bachleitner-Hofmann T; Lanza G; Stork-Sloots L; Maru D; Simon I; Capellà G; Salazar R
Oncologist; 2015 Feb; 20(2):127-33. PubMed ID: 25561511
[TBL] [Abstract][Full Text] [Related]
12. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer.
Nitsche U; Rosenberg R; Balmert A; Schuster T; Slotta-Huspenina J; Herrmann P; Bader FG; Friess H; Schlag PM; Stein U; Janssen KP
Ann Surg; 2012 Nov; 256(5):763-71; discussion 771. PubMed ID: 23095620
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer.
Rimkus C; Martini M; Friederichs J; Rosenberg R; Doll D; Siewert JR; Holzmann B; Janssen KP
Br J Cancer; 2006 Nov; 95(10):1419-23. PubMed ID: 17088907
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle proteins predict recurrence in stage II and III colon cancer.
Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
[TBL] [Abstract][Full Text] [Related]
15. Cdc2 as prognostic marker in stage UICC II colon carcinomas.
Meyer A; Merkel S; Brückl W; Schellerer V; Schildberg C; Campean V; Hohenberger W; Croner RS
Eur J Cancer; 2009 May; 45(8):1466-73. PubMed ID: 19223178
[TBL] [Abstract][Full Text] [Related]
16. Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer.
Jiang Y; Casey G; Lavery IC; Zhang Y; Talantov D; Martin-McGreevy M; Skacel M; Manilich E; Mazumder A; Atkins D; Delaney CP; Wang Y
J Mol Diagn; 2008 Jul; 10(4):346-54. PubMed ID: 18556775
[TBL] [Abstract][Full Text] [Related]
17. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer.
Mo S; Dai W; Xiang W; Li Y; Feng Y; Zhang L; Li Q; Cai G
Carcinogenesis; 2019 Jul; 40(7):861-870. PubMed ID: 30933267
[TBL] [Abstract][Full Text] [Related]
19. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
[TBL] [Abstract][Full Text] [Related]
20. Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.
Brosens RP; Belt EJ; Haan JC; Buffart TE; Carvalho B; Grabsch H; Quirke P; Cuesta MA; Engel AF; Ylstra B; Meijer GA
Cell Oncol (Dordr); 2011 Jun; 34(3):215-23. PubMed ID: 21717218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
